China's Sinovac Biotech has secured $515 million in funding from a local firm to double the production capacity of its coronavirus vaccine, the companies said on Monday, as it expects efficacy data of its experimental shot this month.

The investment deal also comes as Sinovac expands supply deals and trials of its experimental COVID-19 vaccine CoronaVac with more countries following positive results from early to mid-stage clinical trials.

China's Sino Biopharmaceutical Limited said on Monday a business unit will invest $515 million in Sinovac Life Sciences, a subsidiary of Sinovac, to help development and production of CoronaVac.

The investment will give Sino Biopharmaceutical a 15.03% interest in Sinovac Life Sciences, Sino Biopharmaceutical said in a filing to the Hong Kong Stock Exchange.

Sinovac said in a separate statement that it would be able to manufacture 300 million vaccine doses annually and aims to complete construction of a second production facility by the end of 2020 to increase annual COVID-19 vaccine production capacity to 600 million doses.

Depending on market conditions and the availability of financing, it may seek to further expand its production capacity, Sinovac said.

Sinovac has secured CoronaVac supply deals with several countries including Indonesia, Turkey, Brazil and Chile, and is holding talks with the Philippines for a potential sale.

CoronaVac is also one of three experimental COVID-19 vaccines China has been using to inoculate around 1 million people under an emergency use programme.

Brazil's Butantan Institute biomedical centre, which is running a Phase 3 trial of CoronaVac in the country, said last week that Sinovac was expected to publish efficacy results from its vaccine trials by December 15.

China's Sinovac Biotech has secured $515 million in funding from a local firm to double the production capacity of its coronavirus vaccine, the companies said on Monday, as it expects efficacy data of its experimental shot this month.

China's Sinovac Biotech has secured $515 million in funding from a local firm to double the production capacity of its coronavirus vaccine, the companies said on Monday, as it expects efficacy data of its experimental shot this month. The investment deal also comes as Sinovac expands supply deals and trials of its experimental COVID-19 vaccine CoronaVac with more countries following positive results from early to mid-stage clinical trials. China's Sino Biopharmaceutical Limited said on Monday a business unit will invest $515 million in Sinovac Life Sciences, a subsidiary of Sinovac, to help development and production of CoronaVac. The investment will give Sino Biopharmaceutical a 15.03% interest in Sinovac Life Sciences, Sino Biopharmaceutical said in a filing to the Hong Kong Stock Exchange. Sinovac said in a separate statement that it would be able to manufacture 300 million vaccine doses annually and aims to complete construction of a second production facility by the end of 2020 to increase annual COVID-19 vaccine production capacity to 600 million doses. Depending on market conditions and the availability of financing, it may seek to further expand its production capacity, Sinovac said. Sinovac has secured CoronaVac supply deals with several countries including Indonesia, Turkey, Brazil and Chile, and is holding talks with the Philippines for a potential sale. CoronaVac is also one of three experimental COVID-19 vaccines China has been using to inoculate around 1 million people under an emergency use programme. Brazil's Butantan Institute biomedical centre, which is running a Phase 3 trial of CoronaVac in the country, said last week that Sinovac was expected to publish efficacy results from its vaccine trials by December 15.

China's Sinovac secures $515 million to boost covid vaccine production 

Indonesia received its first shipment of coronavirus vaccine from China on Sunday, President Joko Widodo said, as the government prepares a mass inoculation programme. 
 
Jokowi, as the president is widely known, said in an online briefing that the Southeast Asian country received 1.2 million doses from China`s Sinovac Biotech Ltd., a vaccine Indonesia has been testing since August.

Also read|&nbsp;<a href="https://www.wionews.com/india-news/pfizer-seeks-emergency-approval-for-covid-vaccine-in-india-347819" hreflang="en">Pfizer seeks emergency approval for Covid vaccine in India</a> 
 
He added that the government plans to receive another 1.8 million doses in early January. 
 
Late-stage trials of the Sinovac vaccine are also under way in Brazil and Turkey, with interim results on efficiency from Brazil expected by mid-December.

Also read|&nbsp;<a href="https://www.wionews.com/world/world-food-programme-warns-2021-will-bring-catastrophic-humanitarian-crisis-347960">World Food Programme warns 2021 will bring 'catastrophic' humanitarian crisis</a> 
 
Indonesia is also expected this month to receive shipments of raw materials to produce 15 million doses and materials for 30 million doses next month, the president said. 
 
The vaccine still needs to be evaluated by the country`s food and drug agency (BPOM) while his administration continues to prepare for distributing the vaccine across the vast archipelago of 270 million people, Jokowi said. 
 
"We have been preparing for months through simulations in several provinces and I am sure that once it is decided that we can begin the vaccination, everything will be ready," he said. 
 
Indonesia`s daily number of coronavirus infections have accelerated in recent weeks, with total confirmed cases reaching 575,796 on Sunday with 17,740 deaths, the highest in Southeast Asia.

Indonesia received its first shipment of coronavirus vaccine from China on Sunday, President Joko Widodo said, as the government prepares a mass inoculation programme.

Indonesia received its first shipment of coronavirus vaccine from China on Sunday, President Joko Widodo said, as the government prepares a mass inoculation programme. Jokowi, as the president is widely known, said in an online briefing that the Southeast Asian country received 1.2 million doses from China`s Sinovac Biotech Ltd., a vaccine Indonesia has been testing since August. Also read| Pfizer seeks emergency approval for Covid vaccine in India He added that the government plans to receive another 1.8 million doses in early January. Late-stage trials of the Sinovac vaccine are also under way in Brazil and Turkey, with interim results on efficiency from Brazil expected by mid-December. Also read| World Food Programme warns 2021 will bring 'catastrophic' humanitarian crisis Indonesia is also expected this month to receive shipments of raw materials to produce 15 million doses and materials for 30 million doses next month, the president said. The vaccine still needs to be evaluated by the country`s food and drug agency (BPOM) while his administration continues to prepare for distributing the vaccine across the vast archipelago of 270 million people, Jokowi said. "We have been preparing for months through simulations in several provinces and I am sure that once it is decided that we can begin the vaccination, everything will be ready," he said. Indonesia`s daily number of coronavirus infections have accelerated in recent weeks, with total confirmed cases reaching 575,796 on Sunday with 17,740 deaths, the highest in Southeast Asia.

Indonesia receives first COVID vaccine from China's Sinovac

Bangladesh has rejected Chinese vaccine. It is finally distancing itself from Beijing. Palki Sharma Upadhyay asks - Can India seize the moment? Perhaps, start with settling the Teesta water dispute?

Gravitas: Teesta water dispute, Time to settle it?

Chinese drugmaker Sinovac, which is developing a COVID-19 vaccine has broken its promise to Bangladesh. Sinovac has told Bangladesh that it needs to co-finance the effort if it wanted phase-3 trials to take place in the country.

"They (Sinovac Biotech Ltd) sent a letter to Bangladesh government seeking co-financing for performing phase-3 human trial," Abdul Mannan, the health division secretary of Bangladesh, was quoted as saying by The Daily Star, Bangladesh's largest circulating English language newspaper.

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-chinese-company-refuses-to-honour-vaccine-deal-with-bangladesh-332780/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

As per The Daily Star, Sinovac had made an agreement with Bangladesh saying that it would bear the cost of the phase-3 trials itself.

In a letter to Bangladesh dated September 24, Sinovac said that the trials would get delayed unless Bangladesh co-financed the efforts. No specific amount has been mentioned by Sinovac as yet

"It may take some time to reach a concrete decision on co-funding the vaccine trial . . . (but) Bangladesh government is sincerely thinking about the matter keeping in mind the issue of public benefits," Mannan said.

Also Read: <a href="https://www.wionews.com/south-asia/us-bangladesh-take-part-in-high-level-consultation-on-economic-partnership-331781">US, Bangladesh take part in high-level consultation on economic partnership</a>

Dr Abul Bashar Mohammad Khurshid Alam, the chief professor at Directorate General of Health Services said that Bangladesh government was positive about the proposal.

However, officials familiar with the fresh development said they received Sinovac's proposal seeking the co-funding on September 22.

Bangladesh continues to report a surge in the number of coronavirus cases, with the current infections number standing at 368,690. The total number of deaths due to the deadly virus stands at 5,348, local media reported.

(With PTI inputs)

Chinese drugmaker Sinovac, which is developing a COVID-19 vaccine has broken its promise to Bangladesh. Sinovac has told Bangladesh that it needs to co-finance the effort if it wanted phase-3 trials to take place in the country.

Chinese drugmaker Sinovac, which is developing a COVID-19 vaccine has broken its promise to Bangladesh. Sinovac has told Bangladesh that it needs to co-finance the effort if it wanted phase-3 trials to take place in the country. "They (Sinovac Biotech Ltd) sent a letter to Bangladesh government seeking co-financing for performing phase-3 human trial," Abdul Mannan, the health division secretary of Bangladesh, was quoted as saying by The Daily Star, Bangladesh's largest circulating English language newspaper. As per The Daily Star, Sinovac had made an agreement with Bangladesh saying that it would bear the cost of the phase-3 trials itself. In a letter to Bangladesh dated September 24, Sinovac said that the trials would get delayed unless Bangladesh co-financed the efforts. No specific amount has been mentioned by Sinovac as yet "It may take some time to reach a concrete decision on co-funding the vaccine trial . . . (but) Bangladesh government is sincerely thinking about the matter keeping in mind the issue of public benefits," Mannan said. Also Read: US, Bangladesh take part in high-level consultation on economic partnership Dr Abul Bashar Mohammad Khurshid Alam, the chief professor at Directorate General of Health Services said that Bangladesh government was positive about the proposal. However, officials familiar with the fresh development said they received Sinovac's proposal seeking the co-funding on September 22. Bangladesh continues to report a surge in the number of coronavirus cases, with the current infections number standing at 368,690. The total number of deaths due to the deadly virus stands at 5,348, local media reported. (With PTI inputs)

Chinese firm breaks promise made to Bangladesh on COVID-19 vaccine trials

Chinese drugmaker Sinovac, which is developing a COVID-19 vaccine has broken its promise to Bangladesh.

Chinese company seeks co-financing for phase-3 trial in Bangladesh

Final Phase three trials of a Chinese coronavirus vaccine began in Turkey's northwestern province of Kocaeli as vaccine maker Sinovac Biotech unveiled plans on Friday (September 25) to widen its test with children and adolescents later this month.

WION Dispatch: Inside a Chinese COVID-19 vaccine factory

The vaccines are being used at home and China is even selling them abroad. 
&nbsp; 
The Philippines will have quick access to Chinese coronavirus vaccine. China has also been offering loans for vaccines which is a whole new chapter in its debt diplomacy. China will give $1 billion as a loan to Latin America and Caribbean nations to just buy a Chinese vaccine.

When Xi Jinping says public good, you should know its a sales pitch - or worse, a debt trap.&nbsp;

Bangladesh has been promised more than 100,000 free doses from a Chinese company in return, Sinovac has been allowed to run vaccine trials in Bangladesh. Another company - Sinopharm has dispatched a team to Peru. They are recruiting up to 6,000 volunteers for trials there. The world right now is desperate for a vaccine and smaller countries have little choice, so they are taking what China offers.

Indonesia has been locked in a territorial dispute with China in the South China Sea but&nbsp;it wants a vaccine from China. Fifteen days ago Indonesian President Joko Widodo spoke to Xi Jinping over the phone and the Chinese president assured him.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-china-is-selling-its-vaccine-without-a-stamp-of-approval-327797/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

A statement from Beijing said: "China takes seriously Indonesia's concerns and needs in vaccine cooperation." Another South China Sea rival, the Philippines wants vaccine from China. President Rodrigo Duterte made a plea to Xi Jinping in July. He even ruled out confronting Beijing in the South China Sea just to secure a vaccine. Needless to say, China is happy to oblige - it will prioritise the Philippines.

China has offered vaccines to Africa, Latin America, the Caribbean, Middle-East and South Asia and make no mistake it isn't philanthropy and kindness - public good, as the Chinese call it. This is vaccine diplomacy.

China tried something like this with Wuhan virus supplies as countries around the world complained about faulty supplies. China tried to shut them up, threaten them, run propaganda but the truth got out and its supplies were unceremoniously returned.

The vaccines are being used at home and China is even selling them abroad. The Philippines will have quick access to Chinese coronavirus vaccine. China has also been offering loans for vaccines which is a whole new chapter in its debt diplomacy.

The vaccines are being used at home and China is even selling them abroad. The Philippines will have quick access to Chinese coronavirus vaccine. China has also been offering loans for vaccines which is a whole new chapter in its debt diplomacy. China will give $1 billion as a loan to Latin America and Caribbean nations to just buy a Chinese vaccine. When Xi Jinping says public good, you should know its a sales pitch - or worse, a debt trap. Bangladesh has been promised more than 100,000 free doses from a Chinese company in return, Sinovac has been allowed to run vaccine trials in Bangladesh. Another company - Sinopharm has dispatched a team to Peru. They are recruiting up to 6,000 volunteers for trials there. The world right now is desperate for a vaccine and smaller countries have little choice, so they are taking what China offers. Indonesia has been locked in a territorial dispute with China in the South China Sea but it wants a vaccine from China. Fifteen days ago Indonesian President Joko Widodo spoke to Xi Jinping over the phone and the Chinese president assured him. × A statement from Beijing said: "China takes seriously Indonesia's concerns and needs in vaccine cooperation." Another South China Sea rival, the Philippines wants vaccine from China. President Rodrigo Duterte made a plea to Xi Jinping in July. He even ruled out confronting Beijing in the South China Sea just to secure a vaccine. Needless to say, China is happy to oblige - it will prioritise the Philippines. China has offered vaccines to Africa, Latin America, the Caribbean, Middle-East and South Asia and make no mistake it isn't philanthropy and kindness - public good, as the Chinese call it. This is vaccine diplomacy. China tried something like this with Wuhan virus supplies as countries around the world complained about faulty supplies. China tried to shut them up, threaten them, run propaganda but the truth got out and its supplies were unceremoniously returned.

Now, China targets South China Sea rivals with vaccine diplomacy

After Russia, these COVID-19 vaccines set to unveil soon!

The first shipment of a potential COVID-19 vaccine being developed by China has now landed in Brazil. Sao Paulo has received 20,000 doses of CoronaVac which is being developed with a Chinese frim Sinovac. Watch report.

Why is China conducting Phase-3 trials in other countries: China's vaccine test to start in Brazil

Coronavirus pandemic: Brazil to start clinical trials of Chinese vaccine candidate

sinovac

Sinovac, News on Sinovac, stories on Sinovac, articles on Sinovac, Sinovac stories at Wion, Sinovac news, Sinovac latest news